// App-Quantinova.ai

PO1851 : Comparative Efficacy of Ravulizumab and Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome: An Indirect Comparison Using Clinical Trial Data

Researchers

Presenter

  • Rondeau Eric

Principal Investigators

  • Hatswell AnthonyJ

  • Cataland SperoR

  • Chen Peter

  • Freemantle Nicholas

  • Myren Karl-Johan

  • Lommele Asa

  • Wang Yan

  • Deighton Kevin

  • Knowles Emma

  • Sheerin NeilS

  • Tomazos Ioannis

Medical Centers

  • Hôpital Tenon APHP and Sorbonne Université Paris France

  • Delta Hat Limited Nottingham United Kingdom

  • The Ohio State University, Columbus, Ohio, United States

  • Scott, Alexion Pharmaceuticals, Inc., Boston, Massachusetts, United States

  • Kings College London, London, United Kingdom

  • Newcastle University, Newcastle upon Tyne, United Kingdom

Locations

  • France

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Blood/haematological Diseases

Disease

  • Atypical hemolytic uremic syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved